Short answer
Mineralys Therapeutics, Inc. (MLYS) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$37M
- +34.5% YoY · +14.7% QoQ
- EPS (diluted)
- −$0.50
- +56.1% YoY · +23.1% QoQ
Source: XBRL data from the Mineralys Therapeutics, Inc. (MLYS) Q3 2025 10-Q on SEC EDGAR. USD.
Mineralys Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: Government shutdown since Oct 1, 2025 causing FDA furloughs and halting critical regulatory activities
- Most materially updated risk: Expanded inflation risk due to new U.S. trade policies and tariffs affecting pharmaceutical ingredient costs and supply chain
- Regulatory risk: Uncertainty from tax law changes including Inflation Reduction Act and One Big Beautiful Bill Act with pending regulatory guidance
- Operational risk: Delays in FDA product reviews and approvals caused by funding shortages, government shutdowns, and potential future pandemics
- Financial risk: Economic uncertainty from inflation and trade tensions increasing cost of financing and possibly impairing liquidity and funding access
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mineralys Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.